IL142216A0 - A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same - Google Patents

A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same

Info

Publication number
IL142216A0
IL142216A0 IL14221699A IL14221699A IL142216A0 IL 142216 A0 IL142216 A0 IL 142216A0 IL 14221699 A IL14221699 A IL 14221699A IL 14221699 A IL14221699 A IL 14221699A IL 142216 A0 IL142216 A0 IL 142216A0
Authority
IL
Israel
Prior art keywords
wti
native
pharmaceutical compositions
same
immunogenic portion
Prior art date
Application number
IL14221699A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of IL142216A0 publication Critical patent/IL142216A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL14221699A 1998-09-30 1999-09-30 A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same IL142216A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
IL142216A0 true IL142216A0 (en) 2002-03-10

Family

ID=26860363

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14221699A IL142216A0 (en) 1998-09-30 1999-09-30 A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
IL142216A IL142216A (en) 1998-09-30 2001-03-22 Polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142216A IL142216A (en) 1998-09-30 2001-03-22 Polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same

Country Status (25)

Country Link
EP (1) EP1117687B1 (ar)
JP (3) JP4243792B2 (ar)
KR (1) KR100752065B1 (ar)
CN (1) CN100486995C (ar)
AR (1) AR021849A1 (ar)
AT (1) ATE399179T1 (ar)
AU (1) AU6407899A (ar)
BR (1) BR9914116A (ar)
CA (1) CA2349442C (ar)
CZ (1) CZ20011144A3 (ar)
DE (1) DE69938970D1 (ar)
ES (1) ES2310052T3 (ar)
HK (1) HK1039782B (ar)
HU (1) HUP0103598A3 (ar)
IL (2) IL142216A0 (ar)
MX (1) MXPA01003344A (ar)
MY (1) MY139226A (ar)
NO (1) NO325839B1 (ar)
NZ (1) NZ510600A (ar)
PL (1) PL201881B1 (ar)
RU (1) RU2237674C2 (ar)
SA (1) SA00200872B1 (ar)
TR (1) TR200101482T2 (ar)
TW (1) TWI285648B (ar)
WO (1) WO2000018795A2 (ar)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0879282T3 (da) 1996-01-17 2003-10-20 Imp College Innovations Ltd Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)
CN1178956C (zh) 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
AU2001247220A1 (en) * 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
KR100863853B1 (ko) 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
WO2003002142A1 (en) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
AU2003242305A1 (en) * 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
DE60329201D1 (de) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
JP4566912B2 (ja) 2003-06-27 2010-10-20 株式会社癌免疫研究所 Ｗｔ１ワクチン適応患者の選択方法
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
ES2587980T3 (es) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
CN102850434B (zh) * 2006-10-17 2016-04-13 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
EP2479275B1 (en) * 2006-12-28 2015-10-28 International Institute of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
RU2009135802A (ru) * 2007-02-27 2011-04-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) Способ активации хелперных т-клеток и композиция для применения в данном способе
EP2125868B1 (en) * 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
MX343633B (es) 2007-03-05 2016-11-11 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
CN101888852B (zh) * 2007-12-05 2017-02-08 株式会社癌免疫研究所 癌症疫苗组合物
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CA2762586C (en) * 2009-05-19 2018-06-19 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
EP2694553B1 (en) * 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
TWI646970B (zh) 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助ｔ細胞的方法
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
AU2014244860B2 (en) * 2013-03-29 2018-07-26 International Institute Of Cancer Immunology, Inc. WT1-antigen peptide conjugate vaccine
JP6634287B2 (ja) * 2013-05-13 2020-01-22 株式会社癌免疫研究所 免疫療法の臨床効果の予測法
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
CN106029699B (zh) 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
KR20230141904A (ko) * 2014-12-11 2023-10-10 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
KR20180048992A (ko) * 2015-09-10 2018-05-10 메모리얼 슬로안-케터링 캔서 센터 T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법
HRP20220994T1 (hr) * 2015-11-20 2022-11-11 Memorial Sloan Kettering Cancer Center Sastav za liječenje raka
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
CR20190508A (es) * 2017-04-10 2020-01-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
MX2021003660A (es) 2018-09-28 2021-05-28 Sumitomo Pharma Co Ltd Composicion inyectable.
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
EP4149534A4 (en) * 2020-05-12 2024-09-04 Cue Biopharma Inc MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
CA3228494A1 (en) 2021-08-12 2023-02-16 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treating or preventing cancer
CN118076378A (zh) * 2021-09-24 2024-05-24 株式会社车疫苗研究所 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
AU3896899A (en) * 1998-05-11 1999-11-29 Salk Institute For Biological Studies, The Compositions for the treatment of tumors, and uses thereof
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原

Also Published As

Publication number Publication date
EP1117687A2 (en) 2001-07-25
TR200101482T2 (tr) 2002-01-21
CZ20011144A3 (cs) 2002-06-12
HK1039782A1 (en) 2002-05-10
CN100486995C (zh) 2009-05-13
JP2007001984A (ja) 2007-01-11
DE69938970D1 (de) 2008-08-07
AR021849A1 (es) 2002-08-07
PL348595A1 (en) 2002-06-03
TW200606176A (en) 2006-02-16
AU6407899A (en) 2000-04-17
MY139226A (en) 2009-08-28
EP1117687B1 (en) 2008-06-25
SA00200872B1 (ar) 2007-01-30
BR9914116A (pt) 2002-01-15
CA2349442C (en) 2012-12-04
JP4243792B2 (ja) 2009-03-25
JP4235984B2 (ja) 2009-03-11
ATE399179T1 (de) 2008-07-15
RU2237674C2 (ru) 2004-10-10
NO325839B1 (no) 2008-07-28
NZ510600A (en) 2003-12-19
MXPA01003344A (es) 2004-04-21
NO20011613L (no) 2001-05-29
WO2000018795A9 (en) 2000-08-31
HUP0103598A3 (en) 2005-11-28
PL201881B1 (pl) 2009-05-29
JP2002525099A (ja) 2002-08-13
NO20011613D0 (no) 2001-03-29
JP2008069172A (ja) 2008-03-27
KR100752065B1 (ko) 2007-08-28
IL142216A (en) 2009-06-15
TWI285648B (en) 2007-08-21
HUP0103598A2 (hu) 2002-01-28
CN1336935A (zh) 2002-02-20
ES2310052T3 (es) 2008-12-16
HK1039782B (zh) 2008-11-14
WO2000018795A2 (en) 2000-04-06
WO2000018795A3 (en) 2000-10-26
KR20010085861A (ko) 2001-09-07
CA2349442A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
IL142216A0 (en) A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
IL145620A0 (en) A polypeptide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
IL149754A0 (en) Polypeptides containing an immunogenic portion of a chlamydia antigen and pharmaceutical compositions containing the same
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
IL137904A0 (en) Peptide analogues of insulin and pharmaceutical compositions containing the same
IL137417A0 (en) Polypeptides containing at least a portion of a lung tumor protien and pharmaceutical compositions containing the same
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
IL143633A0 (en) Peptides containing ovarian carcinoma proteins and pharmaceutical compositions and vaccines containing the same
IL191904A0 (en) Pharmaceutical and compositions containing a?? fragments
IL133210A0 (en) Lh-rh peptide analogues their uses and pharmaceutical compositions containing them
IL131319A0 (en) 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same
HUP0004398A3 (en) Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
ZA983849B (en) Pharmaceutical compositions of tizoxanide and nitazoxanide.
IL145733A0 (en) A polpyeptide containing an immunogenic portion of a breast protein and pharmaceutical compositions containing the same
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
HUP0100102A3 (en) Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
HUP0003189A3 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
HUP0003330A3 (en) Pharmaceutical compositions containing tizoxanide and nitazoxanide
IL126734A0 (en) Cosmetic and/or pharmaceutical and/or dermatological compositions
IL136045A0 (en) Pyridylpyrrole derivatives and pharmaceutical compositions containing the same
IL125262A0 (en) Synthetic peptides and pharmaceutical compositions comprising them
ZA9811105B (en) Cosmetic and pharmaceutical composition